Cargando…

Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes

BACKGROUND: Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator that has beneficial effects on glucose and lipid metabolism. However, plasma FGF21 levels are paradoxically increased in type 2 diabetes mellitus (T2DM) and obesity, suggesting resistance to this ligand. FGF21 acts mainly...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Eun Shil, Lim, Cheong, Choi, Hye Yeon, Lee, Yun Kyung, Ku, Eu Jeong, Moon, Jae Hoon, Park, Kyong Soo, Jang, Hak Chul, Choi, Sung Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861080/
https://www.ncbi.nlm.nih.gov/pubmed/31798902
http://dx.doi.org/10.1136/bmjdrc-2019-000776
_version_ 1783471279760736256
author Hong, Eun Shil
Lim, Cheong
Choi, Hye Yeon
Lee, Yun Kyung
Ku, Eu Jeong
Moon, Jae Hoon
Park, Kyong Soo
Jang, Hak Chul
Choi, Sung Hee
author_facet Hong, Eun Shil
Lim, Cheong
Choi, Hye Yeon
Lee, Yun Kyung
Ku, Eu Jeong
Moon, Jae Hoon
Park, Kyong Soo
Jang, Hak Chul
Choi, Sung Hee
author_sort Hong, Eun Shil
collection PubMed
description BACKGROUND: Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator that has beneficial effects on glucose and lipid metabolism. However, plasma FGF21 levels are paradoxically increased in type 2 diabetes mellitus (T2DM) and obesity, suggesting resistance to this ligand. FGF21 acts mainly on adipose tissue and ectopic fat accumulation is a typical feature in metabolic deterioration such as diabetes, metabolic syndrome, and cardiovascular disease. OBJECTIVE: To investigate the relationship between FGF21 resistance and ectopic fat accumulation. RESEARCH DESIGN AND METHODS: Subjects who underwent 64-slice multidetector CT (MDCT) were enrolled (n=190). Plasma FGF21 levels and MDCT data of ectopic fats at various sites were analyzed. Human visceral and subcutaneous fat tissues from abdominal and coronary artery bypass surgery were obtained. FGF21 receptor expression and postreceptor signaling in different fat deposits of both control and T2DM subjects were analyzed. RESULTS: Plasma FGF21 levels were significantly associated with body mass index, triglyceride, homeostatic model assessment of insulin resistance, and Matsuda index. Plasma FGF21 levels were significantly higher in patients with T2DM than in the pre-diabetes and normal glucose tolerance groups. The ectopic fat phenotypes (visceral, epicardial, intrahepatic, and intramuscular fat) of T2DM were significantly higher than controls. Plasma FGF21 levels were elevated and exhibited a strong positive correlation with ectopic fat accumulation in T2DM. The expression of genes comprising the FGF21 signaling pathway was also lower in visceral fat than in subcutaneous fat in this disease. CONCLUSIONS: Human FGF21 resistance in T2DM could result from increases in FGF21-resistant ectopic fat accumulation. Our study provides novel clinical evidence linking FGF21 resistance and T2DM pathogenesis.
format Online
Article
Text
id pubmed-6861080
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-68610802019-12-03 Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes Hong, Eun Shil Lim, Cheong Choi, Hye Yeon Lee, Yun Kyung Ku, Eu Jeong Moon, Jae Hoon Park, Kyong Soo Jang, Hak Chul Choi, Sung Hee BMJ Open Diabetes Res Care Metabolism BACKGROUND: Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator that has beneficial effects on glucose and lipid metabolism. However, plasma FGF21 levels are paradoxically increased in type 2 diabetes mellitus (T2DM) and obesity, suggesting resistance to this ligand. FGF21 acts mainly on adipose tissue and ectopic fat accumulation is a typical feature in metabolic deterioration such as diabetes, metabolic syndrome, and cardiovascular disease. OBJECTIVE: To investigate the relationship between FGF21 resistance and ectopic fat accumulation. RESEARCH DESIGN AND METHODS: Subjects who underwent 64-slice multidetector CT (MDCT) were enrolled (n=190). Plasma FGF21 levels and MDCT data of ectopic fats at various sites were analyzed. Human visceral and subcutaneous fat tissues from abdominal and coronary artery bypass surgery were obtained. FGF21 receptor expression and postreceptor signaling in different fat deposits of both control and T2DM subjects were analyzed. RESULTS: Plasma FGF21 levels were significantly associated with body mass index, triglyceride, homeostatic model assessment of insulin resistance, and Matsuda index. Plasma FGF21 levels were significantly higher in patients with T2DM than in the pre-diabetes and normal glucose tolerance groups. The ectopic fat phenotypes (visceral, epicardial, intrahepatic, and intramuscular fat) of T2DM were significantly higher than controls. Plasma FGF21 levels were elevated and exhibited a strong positive correlation with ectopic fat accumulation in T2DM. The expression of genes comprising the FGF21 signaling pathway was also lower in visceral fat than in subcutaneous fat in this disease. CONCLUSIONS: Human FGF21 resistance in T2DM could result from increases in FGF21-resistant ectopic fat accumulation. Our study provides novel clinical evidence linking FGF21 resistance and T2DM pathogenesis. BMJ Publishing Group 2019-11-17 /pmc/articles/PMC6861080/ /pubmed/31798902 http://dx.doi.org/10.1136/bmjdrc-2019-000776 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Metabolism
Hong, Eun Shil
Lim, Cheong
Choi, Hye Yeon
Lee, Yun Kyung
Ku, Eu Jeong
Moon, Jae Hoon
Park, Kyong Soo
Jang, Hak Chul
Choi, Sung Hee
Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes
title Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes
title_full Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes
title_fullStr Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes
title_full_unstemmed Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes
title_short Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes
title_sort plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes
topic Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861080/
https://www.ncbi.nlm.nih.gov/pubmed/31798902
http://dx.doi.org/10.1136/bmjdrc-2019-000776
work_keys_str_mv AT hongeunshil plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes
AT limcheong plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes
AT choihyeyeon plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes
AT leeyunkyung plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes
AT kueujeong plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes
AT moonjaehoon plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes
AT parkkyongsoo plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes
AT janghakchul plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes
AT choisunghee plasmafibroblastgrowthfactor21levelsincreasewithectopicfataccumulationanditsreceptorlevelsaredecreasedinthevisceralfatofpatientswithtype2diabetes